Targeting Praja2 has shown therapeutic potential in preclinical models, where the use of transferrin-targeted self-assembling nanoparticles (SANPs) loaded with siRNA against Praja2 effectively inhibited GBM growth and improved survival in mouse models [2]. This evidence concerns the gene PJA2 and glioblastoma.